

type of report	Current report
number	26/2012
company	PHARMENA

Order for production of tablets within the 1-MNA project

The Management Board of PHARMENA S.A. informs that a subsidiary company Cortria Corp. (USA) has commissioned production of tablets containing active substance 1-MNA within its framework agreement with AAIPharma Inc. (USA). The production of tablets is indispensable for further clinical trials on innovative anti-atherosclerosis medicinal product 1-MNA.

The order for the production lies within the realisation of the Company's updated Strategy for 2012-2015 in the scope of anti-atherosclerosis medicinal product project (the Issuer informed about the strategy's assumptions in current report no. 16/2012 of 13th April 2012).

AAIPharma Inc. is a global supplier in pharmaceutical, biotechnological and medical industry. AAIPharma offers its services in, among others: analytical chemistry, formulation development, manufacturing (GMP), repackaging and distribution.

The information is made public due to the fact that the production of tablets containing active substance 1-MNA is essential for further clinical trials on anti-atherosclerosis medicinal product and commercialisation of this project. Potential revenue resulting from the commercialisation of anti-atherosclerosis medicinal product may have significant influence on the Issuer's financial and economic situation.

Legal basis: Alternative Trading System Rules – Exhibit 3 “Current and Periodical Information in the Alternative Trading System on the NewConnect Market”, Article 3 (1).

Representatives of the company:

- Konrad Palka - President of the Board
- Marzena Wieczorkowska – Vice President of the Board